title: Pathogenetic aspects of responsiveness to ondansetron (5-hydroxytryptamine type 3 receptor antagonist) in patients with primary fibromyalgia syndrome--a preliminary study.
abstract: OBJECTIVE
  To study the efficacy of 5-hydroxytryptamine type 3 receptor (5-HT-3R) antagonist (ondansetron) vs paracetamol in primary fibromyalgia (FM) syndrome.
  
  
  METHODS
  A double blind, crossover, latin square study of 21 patients with FM. Visual analog scale (VAS) and body drawings were used to record pain intensity. Functional symptoms were determined for using a Likert-type self-developed protocol. Quantitative dolorimetry was applied to assess the number of painful tender points and the average pain threshold. Serum serotonin levels were measured by a commercial ELISA.
  
  
  RESULTS
  A marked improvement in pain intensity measured by VAS (p < 0.005), pain score (p < 0.05), tender points (p < 0.05), and average pain threshold (p < 0.01) was obtained with ondansetron, whereas no improvement was seen with paracetamol. After ondansetron treatment, there was also significant reduction in both functional symptoms (p < 0.01) and headache intensity (p < 0.05). In patients who did not respond to ondansetron there was higher baseline pain intensity measured by VAS (p < 0.05) and pain score (p < 0.01), and a lower pain threshold (p < 0.05) compared to those who did respond well. In the responsive group, no significant differences were seen in the serotonin level before and after therapy. Whereas a significant increase in serum serotonin concentration (p < 0.01) was observed in nonresponders after ondansetron treatment.
  
  
  CONCLUSIONS
  Ondansetron appears to be an effective drug in about 50% of patients with FM. There may be 2 subsets of patients with FM that differ clinically and pathogenetically with regard to the disturbance in the 5-HT-3R system.
authors.affiliation: Hochrhein Institute for Rehabilitation Research, Bad Säckingen, Germany/Rheinfelden, Switzerland.
authors.forename: P
authors.initials: P
authors.lastname: Hrycaj
authors.forename: T
authors.initials: T
authors.lastname: Stratz
authors.forename: P
authors.initials: P
authors.lastname: Mennet
authors.forename: W
authors.initials: W
authors.lastname: Müller
mesh_terms: D000082:Acetaminophen / Q000627:therapeutic use; D000328:Adult; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005260:Female; D005356:Fibromyalgia / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017294:Ondansetron / Q000627:therapeutic use*; D010147:Pain Measurement / Q000187:drug effects; D012701:Serotonin / Q000097:blood
chemical_list: D012701:Serotonin; D000082:Acetaminophen; D017294:Ondansetron